Press Releases

Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY

Company continues to make strides towards breakeven NEW HAVEN, CT, Globenewswire – (February 13, 2024) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that [...]

Read More
Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer

NEW HAVEN, CT, Globenewswire – (February 6, 2024) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into a distribution agreement with [...]

Read More
Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter

Results clearly demonstrate the business’s ability to reach breakeven in the near future NEW HAVEN, CT, Globenewswire – (January 23, 2024) – Specialty cancer diagnostics company [...]

Read More
Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan

First order for IV-Cell placed by Major Japanese Laboratory NEW HAVEN, CT, Globenewswire – (January 17, 2024) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) [...]

Read More
Precipio Announces Christina Valauri joins the Board of Directors

Douglas Fisher, MD will step down as Director, and remain as a board observer NEW HAVEN, CT, Globenewswire – (January 2, 2024) – Specialty cancer diagnostics [...]

Read More
Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024

NEW HAVEN, CT, Globenewswire – (December 14, 2023) – Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) shares thoughts and reflections looking back at [...]

Read More
Precipio Announces Q3-2023 Shareholder Update Call

Conference Call to be held on November 20th, 2023 at 5:00 PM EST NEW HAVEN, CT, (November 16th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]

Read More
Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022

28% Revenue Increase is Major Step toward Company Breakeven NEW HAVEN, CT, Globenewswire – (October 18, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]

Read More
Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023

Company anticipates current cash levels sufficient to reach breakeven NEW HAVEN, CT, Globenewswire – (October 3rd, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]

Read More
Precipio Continues to Sign New HemeScreen™ Customers

New customer orders received in Q3 exceed $1M annualized revenue NEW HAVEN, CT, Globenewswire – (September 28th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced [...]

Read More
Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven

Higher pathology revenues and lower cost structure drive down product revenue breakeven point from $8M to $6M NEW HAVEN, CT, Globenewswire – (September 25th, 2023) – [...]

Read More
Precipio Takes Final Step Towards Regaining Nasdaq Compliance

Company announces 1-for-20 reverse stock split NEW HAVEN, CT – (September 21, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that [...]

Read More
Precipio’s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan

Company continues to make strides towards profitability NEW HAVEN, CT, Globenewswire – (September 13, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces its [...]

Read More
Precipio Announces Q2-2023 Shareholder Update Call

Conference Call to be held on August 17, 2023 at 5:00 PM EST NEW HAVEN, CT, (August 10th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]

Read More
Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel

Advanced panel already generating six-figure pre-orders NEW HAVEN, CT, Globenewswire – (August 8, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch [...]

Read More
Precipio’s Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven

Revenue growth and customer pipeline advance the Company towards breakeven NEW HAVEN, CT, Globenewswire – (August 3, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Read More
Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023

Revenue growth and customer pipeline advance the Company towards breakeven NEW HAVEN, CT, Globenewswire – (August 1, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Read More
Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology

New panel will enable rapid, precise genetic profiling of patients with deadly disease NEW HAVEN, CT, (June 13th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]

Read More
Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

NEW HAVEN, CT, (June 8th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced it has entered into securities purchase agreements with certain institutional investors [...]

Read More
Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects

Independent of revenue growth, these Projects expected to decrease cash burn by 25% in Q3 NEW HAVEN, CT, (June 7th, 2023) – Specialty cancer diagnostics company Precipio, [...]

Read More
Precipio Shares Growth Catalysts For HemeScreen

Q1 Results and catalysts show promising growth trajectory NEW HAVEN, CT, (May 17th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be discussing on today’s [...]

Read More
Precipio Announces Q1-2023 Shareholder Update Call

Conference Call to be held on May 17, 2023 at 5:00 PM EST NEW HAVEN, CT, (May 15th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]

Read More
Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division

Customer’s pathology services annual revenues expected to exceed $1.5M NEW HAVEN, CT, Globenewswire – (May 4th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another [...]

Read More
Precipio Signs Another HemeScreen™ Customer

Customer’s revenues expected at $750K at full capacity NEW HAVEN, CT, Globenewswire – (May 4th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another agreement [...]

Read More
Precipio Granted 180-day Extension From NASDAQ To Regain Compliance

Extension will enable the Company to execute on its growth and advance toward breakeven NEW HAVEN, CT, Globenewswire – (April 27th, 2023) – Specialty cancer diagnostics [...]

Read More
Precipio Unaudited Q1-2023 Product Revenues Exceed The Two Prior Quarters (Q3+Q4 of 2022) Combined

Q1-2023 product revenues approximately $0.76M exceeded the $0.66M combined revenue of Q3+Q4 2022 NEW HAVEN, CT, Globenewswire – (April 19th, 2023) – Specialty cancer diagnostics company [...]

Read More
Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call

Conference Call to be held on Monday, April 3rd, 2023 at 5:00 PM EST NEW HAVEN, CT, Globenewswire – (March 28th, 2023) – Specialty cancer diagnostics [...]

Read More
Precipio Ships First IV-Cell® Order to Major US Healthcare System

Products Division revenues begin to diversify beyond HemeScreen® NEW HAVEN, CT, Globenewswire – (March 21st, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) delivered its first [...]

Read More
Precipio continues to sign up and onboard HemeScreen™ customers

Conversion from sales funnels developed with distribution partners alongside direct sales points to continued accelerated growth NEW HAVEN, CT, Globenewswire – (March 7th, 2023) – Specialty [...]

Read More
Precipio’s HemeScreen® Selected as 2022 Best New Product

HemeScreen® Technology and Product Line were recognized by Fisher Healthcare during recent National Sales Meeting “We are privileged to have Fisher Healthcare as a distribution [...]

Read More
Precipio Signs Another Major HemeScreen™ Customer

Customer’s initial annual revenue expected at $650K, $2.0M revenue at full capacity NEW HAVEN, CT, Globenewswire – (January 11th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Read More
Precipio Signs Additional Major HemeScreen™ Customer

Customer to begin gradually onboarding panels in Q1-2023, potential $1.2M revenue at full capacity NEW HAVEN, CT, Globenewswire – (December 6th, 2022) – Specialty cancer diagnostics [...]

Read More
Precipio Presents Poster on HemeScreen® Study at Association of Molecular Pathology (AMP) 2022 Annual Conference

Poster presents findings of a study of ~1000 patient samples demonstrating superior accuracy for HemeScreen™ MPN Assay NEW HAVEN, CT, Globenewswire – (November 7th, 2022) – [...]

Read More
Precipio Announces Third Quarter Shareholder Update Call

Conference Call to be held on Monday, November 14th, 2022 at 5:00 PM ET NEW HAVEN, CT, Globenewswire – (November 2nd, 2022) – Specialty cancer diagnostics [...]

Read More
Precipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen™

Adding customer segment exceeding $100M in market potential NEW HAVEN, CT, Globenewswire – (September 15th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has signed a [...]

Read More
Sharon Robins Joins Precipio’s Products Division As Senior Director Of Laboratory & Hospital Sales

Precipio continues to build strong team in anticipation of substantial growth in the next 12 months NEW HAVEN, CT, Globenewswire – (August 24th, 2022) – Specialty [...]

Read More
Precipio Launches New 1-Step Technology For All HemeScreen Assays

New technology enables same day test results by eliminating extra confirmation step NEW HAVEN, CT, Globenewswire – (August 16th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Read More
Toni-Ann Mills Joins Precipio’s Products Division To Lead Channel Partner Training, Learning & Development

Precipio prepares to launch a nationwide HemeScreen sales effort of 250+ sales reps from AmerisourceBergen, ThermoFisher, and other distributors NEW HAVEN, CT, Globenewswire – (August [...]

Read More
Precipio Announces Second Quarter Shareholder Update Call

Conference Call to be held on Monday, August 15th, 2022 at 5:00 PM EST NEW HAVEN, CT, Globenewswire – (August 8th, 2022) – Specialty cancer diagnostics [...]

Read More
Precipio To Distribute HemeScreen® Through Fisher Healthcare Channel

Agreement Enhances Precipio’s Product Reach to US Laboratories NEW HAVEN, CT – (Globe Newswire) – (July 20th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today [...]

Read More
Precipio Requests That All Stockholders That Have Not Yet Voted, Proceed To Cast Their Vote

Meeting Adjourned, new meeting set for July 5th at 10am EDT NEW HAVEN, CT – (June 14th, 2022) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today [...]

Read More
Keith Meadors Joins Precipio To Lead Its Products Division

Seasoned, experienced industry executive with a track record of managing 9-figure revenue sales organizations NEW HAVEN, CT – (Globenewswire) – (June 13th, 2022) – Specialty cancer [...]

Read More
Precipio Receives CE-IVD Certification To Market Multiple HemeScreen® Panels In Europe

This Regulatory Approval Opens the Company’s Reach to the European Market NEW HAVEN, CT – (Globenewswire) – (May 24th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Read More
Precipio Signs First IV-Cell Customer Agreement

Laboratory operating both HemeScreen® & IV-Cell® demonstrates significant cross-sell potential NEW HAVEN, CT – (Globenewswire) – (May 10th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]

Read More
Precipio Customer American Oncology Network (AON) Selected To Present HemeScreen® Technology Case Study At Industry Leading Clinical Laboratory Conference

NEW HAVEN, CT – (Apr 26th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), is excited to announce its participation and the presentation of HemeScreen, its [...]

Read More
Precipio Announces 2021 Fourth Quarter And Year-End Shareholder Update Call

Conference Call to be held on Monday, April 4th, 2022 at 5:00 PM EST NEW HAVEN, CT, Globenewswire – (Mar 22nd, 2022) – Specialty cancer diagnostics [...]

Read More
Precipio Inc. Announces The Resignation Of Its Chief Financial Officer And Appointment Of Interim CFO

NEW HAVEN, CT, (Mar 21st, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that Mr. Carl Iberger, Precipio’s CFO for the past five years, [...]

Read More
Precipio Releases Year-End 2021 Preliminary Unaudited Results And Outlook For 2022

NEW HAVEN, CT, (Feb 24th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced its unaudited and preliminary results for 2021. The Company anticipates posting [...]

Read More
New York State Approves Precipio’s HemeScreen For POL Clinical Use

New York Cancer & Blood POL will commence the use of HemeScreen in its laboratory NEW HAVEN, CT, (Nov 18th, 2021) – Specialty cancer diagnostics company Precipio, [...]

Read More
Precipio Announces Q3-2021 And Year-End Shareholder Update Call

Conference Call to be held on Monday, November 15th, 2021 at 5:00 PM EST NEW HAVEN, CT, (Nov 1st, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Read More
American Oncology Network Partners With Precipio To Bring HemeScreen® Into AON’s Laboratory

HemeScreen Assays will enable AON to deliver rapid patient diagnostics for hematologic malignancies through advanced molecular screening technology New Haven, CT, and Fort Myers, FL [...]

Read More
Precipio Reschedules Q2-2021 Shareholder Update Call

Due to a schedule conflict, the call is moved to Thursday August 26th at 5:00PM EST NEW HAVEN, CT, (Aug 20th, 2021) – Specialty cancer diagnostics [...]

Read More
Precipio Announces Q2-2021 And Year-End Shareholder Update Call

Conference Call to be held on Monday, August 23rd, 2021 at 5:00 PM EST NEW HAVEN, CT, (Aug 12th, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Read More
Precipio Announces Preliminary Unaudited Q2-2021 Revenues Of $2.3M

Increase of 65% YoY, and 29% from Q1-2021 due to strong Pathology Growth and HemeScreen NEW HAVEN, CT, (Jul 28th, 2021) – Specialty diagnostics company Precipio, Inc. (NASDAQ: [...]

Read More
Precipio Terminates Its Equity Line

NEW HAVEN, CT, (Jun 15th, 2021) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that as part of management’s review of its current financing arrangements, it has [...]

Read More
Precipio Launches HemeScreen® Anemia Panel, A One-Of-Its-Kind Testing Tool

Laboratories can use this rapid, cost effective test to distinguish malignancy-driven anemia from other causes NEW HAVEN, CT, (June 8th, 2021) – Specialty diagnostics company Precipio, Inc. (NASDAQ: [...]

Read More
Precipio Announces Q1-2021 And Year-End Shareholder Update Call

Conference Call to be held on Thursday, May 20th, 2021 at 5:00 PM EST NEW HAVEN, CT, (May 14th, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Read More
Precipio Launches New HemeScreen Panel For AML, With An Unparalleled 4-Hour Turnaround-Time

Physician Office Laboratory (POL) Customers will be able to immediately integrate this important test into their current operations NEW HAVEN, CT, (May 10th, 2021) – Specialty [...]

Read More
Precipio Launches Its Rapid COVID-19 Antibody Test On Amazon Platform

Nirmidas’ test is available to POC healthcare providers with an Amazon business account NEW HAVEN, CT, (May 3rd, 2021) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced [...]

Read More
Current Signed Customers Expected To Generate $1M Annualized Reported Revenues From Precipio’s HemeScreen POL Offering By Q4-2021

Precipio reaffirms forecast that product revenues will reach approximately 50% of pathology revenue by the fourth quarter of 2021 NEW HAVEN, CT, (April 26th, 2021) – [...]

Read More
Precipio Enters Into An At-The -Market (ATM) Financing Arrangement

NEW HAVEN, CT, (April 5th, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces a new “At-The-Market” (ATM) financing arrangement that improves its financing flexibility. As [...]

Read More
Precipio Announces 95% Annual Growth YoY And 180% Quarterly Growth YoY

HemeScreen projected to rapidly become a material revenue contributor in 2021 NEW HAVEN, CT, (March 30th, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced its [...]

Read More
Precipio Announces Q4-2020 And Year-End Shareholder Update Call

Conference Call to be held on Wednesday, March 31st, 2021 at 5:00 PM EST NEW HAVEN, CT, (March 18th, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Read More
Mr. Ron Andrews Joins Precipio’s Board Of Directors

Company Strengthens Depth of Expertise in Products Industry NEW HAVEN, CT, (March 3rd, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that Mr. Ron Andrews has joined the [...]

Read More
Mr. Richard Sandberg Is Appointed Chairman Of Precipio’s Board Of Directors

NEW HAVEN, CT, (March 3rd, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the Board of Directors. [...]

Read More
Precipio Launches COVID-19 Antibody Testing At Point-Of-Care

Following the receipt of FDA EUA by Nirmidas, Precipio begins market roll out to POC NEW HAVEN, CT, (January 28th, 2021) – Specialty cancer diagnostics company Precipio, [...]

Read More
Precipio Signs HemeScreen™ Deals With Two Leading Oncology Groups

Partnership with ION Solutions expected to accelerate sales NEW HAVEN, CT, (January 20th, 2021) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has signed agreements with two [...]

Read More
Precipio Signs Sales & Marketing Agreement For HemeScreen™ With Major Oncology Distributor

Thousands of Oncology Practices will gain access to HemeScreen POL program NEW HAVEN, CT, (December 10th, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has entered [...]

Read More
Precipio Announces Q3-2020 Shareholder Update Call

Conference Call to be held on Thursday, November 19th, 2020 at 5:00 PM EST NEW HAVEN, CT, (November 11th, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Read More
Precipio & ADS Biotec Launch Seven Beta Sites For IV-Cell™

Prominent Laboratories in US and Europe will begin testing the media NEW HAVEN, CT, (October 6th, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), along with [...]

Read More
Precipio Launches Its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular Panel

Panel of clinically critical genes can yield same-day results outperforming major competitors NEW HAVEN, CT, (September 22nd, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced [...]

Read More
Precipio Announces A Shareholder Call To Discuss Its COVID-19 Progress And Future Plans

Ilan Danieli, Precipio CEO, will address questions from shareholders related to company COVID-19 strategy NEW HAVEN, CT, (September 4th, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Read More
Precipio & ADS Biotec Sign Global Distribution Agreement For IV-Cell™

Partnership is expected to accelerate product introduction to most major labs worldwide NEW HAVEN, CT, (August 20th, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced [...]

Read More
Precipio Announces Q2-2020 Corporate Update Call For Shareholders

Conference Call to be held on Monday, August 17th, 2020 at 5:00 PM EST NEW HAVEN, CT, (August 7th, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Read More
Precipio Launches Covid-19 Antibody Test In Its CLIA Laboratory

Test initially offered to Precipio’s customer base, then expanding distribution reach NEW HAVEN, CT, (August 4th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced it has [...]

Read More
Precipio Announces Commercial Launch Of Covid-19 Antibody Test

Test received FDA EUA; commercialization begins NEW HAVEN, CT, (July 30th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), is announcing its COVID-19 strategy, and its intent [...]

Read More
Precipio Announces Q2-2020 Unaudited Pathology Services Revenue Increased Approximately 50% Over Q1’20

NEW HAVEN, CT, (July 22nd, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced its preliminary unaudited revenues for its pathology services increased from $0.8M in Q1’20, [...]

Read More
Precipio Regains Listing Compliance With NASDAQ Minimum Bid Requirement

NEW HAVEN, CT, (July 1st, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has regained compliance with the Nasdaq listing requirements. On June 29, [...]

Read More
Precipio Adds Another HemeScreen™ Customer

Newly Created Reagent Rental Program Continues to Gain HemeScreen Adopters NEW HAVEN, CT, (June 9th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that Cancer and Hematology [...]

Read More
Q1-2020 Reported Revenues Increase 77% Over Q4-2019 To $1.2M

Precipio Pathology Sales Performance Metrics Demonstrate Growth in Customer Acquisition, Retention, and Total Case Volume NEW HAVEN, CT, (May 15th, 2020) – Specialty cancer diagnostics company Precipio, [...]

Read More
Precipio Announces Q1-2020 Corporate Update Call For Shareholders

Conference Call to be held on Tuesday, May 19th, 2020 at 5:00 PM EST NEW HAVEN, CT, (May 12th, 2020) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Read More
Precipio Launches New HemeScreen™ Reagent Rental Program

Oncology Practices Improve Patient care and Increase Revenue & Profit NEW HAVEN, CT, (April 6th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it [...]

Read More
Company Update During The COVID-19 Era

Letter to the Shareholders from the CEO NEW HAVEN, CT, (March 20th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), released today the following letter to shareholders [...]

Read More
Precipio Completes The Transaction With Poplar Healthcare’s Oncometrix Hematopathology Division

Customer base and sales team transition to Precipio, Doubling Revenues NEW HAVEN, CT, (March 16th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it [...]

Read More
Precipio Achieves Impressive Initial Results Of Artificial Intelligence Decision-Support Tool

Groundbreaking clinical and economic impact to be generated NEW HAVEN, CT, (February 26th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that preliminary results from [...]

Read More
Precipio In Advanced Discussions With Poplar Healthcare Towards A Multi-Faceted Strategic Partnership

NEW HAVEN, CT, (February 18th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it is in advanced discussions with Poplar Healthcare to establish a strategic partnership [...]

Read More
Precipio Provides Clarification To Amendment No.1 To Form S-1 Filing

NEW HAVEN, CT, (January 28th, 2020) – The management team of specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), would like to provide an explanation on the recent Amendment [...]

Read More
Precipio Provides Clarification To Recent S-1 Filing

NEW HAVEN, CT, (January 15th, 2020) – The management team of specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), would like to provide several clarification points related to the [...]

Read More
Precipio Announces Shareholder Update Call To Kick Off 2020

NEW HAVEN, CT, (January 13th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that on Monday, January 20th at 5pm it will conduct a shareholder update [...]

Read More
Precipio Announces First IV-Cell™ Commercial Order From Northwell Health

Largest healthcare provider in New York becomes the first IV-Cell customer NEW HAVEN, CT, (December 17th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced [...]

Read More
Precipio Announces The Resignation Of Samuel Riccitelli And The Introduction Of Richard Sandberg To Its Board Of Directors

Douglas Fisher, MD will assume the role of interim Chairman of the Board NEW HAVEN, CT, (December 4th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced [...]

Read More
Precipio Wins $750,000 Pharma Project

Testing and revenues will begin in Q4 and continue into Q1-2020 NEW HAVEN, CT, (November 14th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced a substantial [...]

Read More
Precipio Reports Superior Performance For IV-Cell™ In Side-By-Side Analysis Conducted By Two Major External Laboratories

Testing yielded substantially better operational and clinical results, including the identification of a Leukemia missed when using a competing media NEW HAVEN, CT, (November 14th, 2019) – Specialty [...]

Read More
Precipio Announces Q3-2019 Corporate Update Call For Shareholders

Conference Call to be held on Wednesday, November 13th, 2019 at 5:30 PM EST NEW HAVEN, CT, (November 4th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Read More
Partners HealthCare And Precipio Enter Into Pathology Services Agreement

Continued Expansion of Academic Expertise Platform NEW HAVEN, CT, (October 9th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today a further expansion of its cancer [...]

Read More
Precipio Announces Shareholder Update Call On Commercial Progress

Conference call to be held Thursday October 10th at 5:00PM EST NEW HAVEN, CT, (October 2nd, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), will hold a [...]

Read More
Clinical Validations For IV-Cell™ And HemeScreen™ Completed

Orders expected from several major labs both domestically and internationally NEW HAVEN, CT, (September 26th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that as it [...]

Read More
Precipio And University Of Pennsylvania Enter Into Joint Collaboration Agreement For Pathology Diagnostics

First cases already diagnosed and reported by Penn expert pathologists NEW HAVEN, CT, (September 5th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today a major [...]

Read More
Precipio Pathology Sales Metrics Demonstrate Continuous Improvement In Q2 2019

Three key metrics indicate growth over prior Quarter and same Quarter of 2018 NEW HAVEN, CT, (August 13th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]

Read More
Precipio Announces Q2-2019 Corporate Update Call For Shareholders

Conference Call to be held on Wednesday, August 21st, 2019 at 5:00 PM EST NEW HAVEN, CT, (August 13, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Read More
Global Expansion Efforts Begin Yielding Results

Asia is the first Key Geographic Focal Point NEW HAVEN, CT, (July 22nd, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that in conjunction with [...]

Read More
Precipio And H3 Biomedicine Sign Second Development Agreement

Companies to create a panel amplifying targeted regions of key cancer genes NEW HAVEN, CT, (June 25th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced the [...]

Read More
Precipio CEO Provides Update Letter To Shareholders

NEW HAVEN, CT, (June 17th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), provides an update to its shareholders. Dear Investors: We are all aware of the [...]

Read More
Precipio Signs Exclusive Manufacturing Agreement For IV-Cell™

NEW HAVEN, CT, (June 4th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has entered into an exclusive subcontracting manufacturing agreement with diagnostics manufacturing [...]

Read More
Precipio Pathology Sales Performance Metrics Demonstrate Substantial Improvement In Q1-2019

Three key metrics are leading indicators of continuous revenue growth NEW HAVEN, CT, (May 30th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), today provides shareholders with [...]

Read More
Precipio CEO Enrolls In Long Term Stock Purchase Plan

NEW HAVEN, CT, (May 23, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that, as previously stated, Ilan Danieli, Precipio’s CEO, has enrolled in a [...]

Read More
Precipio Regains Nasdaq Listing Compliance

NEW HAVEN, CT, (May 15, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that on May 15, 2019 the Company received a letter from Nasdaq informing [...]

Read More
Precipio Conducts IV-Cell™ Validation Trial With A Prominent Laboratory

NEW HAVEN, CT, (May 06, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it is in the process of completing a trial of its Proprietary [...]

Read More
Precipio Successfully Completes Nasdaq Hearing Process

Company is expected to regain listing compliance upon completion of the remaining 10-day requirement NEW HAVEN, CT, (May 03, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]

Read More
Precipio Reminder Of Corporate Update Shareholder Call

Conference Call to be held Monday May 6th, 2019 at 5:00pm Eastern Time NEW HAVEN, CT, (May 01, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), will [...]

Read More
Precipio Signs First Major International Services Contract

Contract expected to generate over $1.5M in revenues annually NEW HAVEN, CT, (April 29, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that it has [...]

Read More
Precipio Takes Final Step Towards Regaining Nasdaq Compliance

Company announces 1-for-15 reverse stock split NEW HAVEN, CT, (April 26, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that it has implemented a 1-for-15 [...]

Read More
Precipio Launches Global Expansion Strategy

Precipio to capitalize on powerful data and expertise to grow business globally NEW HAVEN, CT, (April 24, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch [...]

Read More
Mr. Ori Karev Joins Precipio Executive Team As Chief Strategy Officer

Precipio to expand its reach globally NEW HAVEN, CT, (April 18, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced today that Mr. Ori Karev has joined the [...]

Read More
Precipio Announces 2018 Year-End Corporate Update Call For Shareholders

Conference Call to Be Held On Monday, May 6th, 2019 at 5:00 PM ET NEW HAVEN, CT, (April 15th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Read More
Precipio Identifies Manufacturer For Its IV-Cell Media

Manufacturing Partner enables Precipio to address customer demand and plans for global distribution NEW HAVEN, CT, (April 9th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced today [...]

Read More
Precipio’s HemeScreen™ Adopted By Methodist Health

New Molecular Screening Assay Technology Gains Traction NEW HAVEN, CT, (April 3, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that Methodist Hospital, located in Memphis, [...]

Read More
Precipio CEO Issues Shareholder Update Letter

NEW HAVEN, CT, (March 11th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), issues the following letter from CEO Ilan Danieli. Dear Shareholders, Following our recent [...]

Read More
Precipio Provides Corporate Update Shareholder Call

Conference Call to be held Thursday February 21st, 2019 at 4:30pm Eastern Time NEW HAVEN, CT, (February 18th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO),will [...]

Read More
Precipio 2018 Revenues Increase 66% Over 2017; Company Takes Substantial Cost-Cutting Measures Towards Profitability

Shareholder call scheduled for February 21st at 4:30PM EST NEW HAVEN, CT, (February 14th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO),announced today its preliminary unaudited [...]

Read More
Makati Medical Center In The Philippines Adopts Precipio’s ICE COLD-PCR Mutation Enrichment Technology For Liquid Biopsies

One of Nation’s Premier Hospitals to Become Central Laboratory for Liquid Biopsies NEW HAVEN, CT, (January 15th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that Makati [...]

Read More
Precipio Announces First US Government Customer For ICE COLD-PCR™ Mutation Enrichment Technology

Department of Defense Approves Precipio as a Vendor for its Liquid Biopsy Testing NEW HAVEN, CT, (January 10th, 2019) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]

Read More
Precipio Files Patent For HemeScreen™, Its Novel Molecular Assay

Commercialization of assay underway with both in-house testing and hospital sales NEW HAVEN, CT, (January 8th, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the [...]

Read More
Precipio Reports Strong Mid-Quarter Growth

Key Metrics Indicate Continued Growth QoQ for Fourth Quarter 2018 NEW HAVEN, CT, (December 12th, 2018) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that based [...]

Read More
Precipio Announces $1.2 Million Securities Purchase Agreement With Participation From Members Of Its Board Of Directors, And Other Investors

NEW HAVEN, CT, (December 4th, 2018) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has entered into a $1.2 million Securities Purchase Agreement with [...]

Read More
Precipio Announces Third Quarter 2018 Corporate Update Call For Shareholders

Conference Call to Be Held Monday, November 19, 2018 at 5:00 PM ET NEW HAVEN, CT, (November 15th, 2018) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) will be [...]

Read More
Proxy And Special Shareholder Meeting Letter From CEO

CEO to share a few thoughts in advance of the upcoming shareholder call on Monday, November 19th at 5PM EST NEW HAVEN, CT, (November 16th, [...]

Read More
Webinar To Highlight Technology Underlying Precipio’s ICE COLD-PCR On November 20, 2018

Current Status, Existing and Future Applications of COLD-PCR for Cancer and Prenatal Diagnosis to Be Presented NEW HAVEN, CT, (November 14th, 2018) – Specialty diagnostics company Precipio, [...]

Read More
Precipio And PerkinElmer Collaborate To Provide Solutions For Liquid Biopsy Testing Workflows

Precipio ICE COLD-PCR™ reagents will be sold with PerkinElmer DNA/RNA extraction and isolation products NEW HAVEN, CT, (November 1st, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Read More
Precipio Expands ICE COLD-PCR™ Menu For Breast, Colon And Endometrial Cancers

Ultra-sensitive assays for PIK3CA exons 9 & 20 detect mutations that impact critical therapeutic decisions NEW HAVEN, CT, (October 23rd, 2018) – Precipio, Inc. (NASDAQ: PRPO), announced today [...]

Read More
Innovation Behind Precipio’s ICE-COLD PCR™ Platform Spotlighted In Media

Articles Highlight Scientific and Economic Advantages Provided by Precipio’s Technology NEW HAVEN, CT, (October 18th, 2018) – The scientific and economic advantages of the proprietary, ultra-sensitive [...]

Read More
Precipio Launches HemeScreen™, A Disruptive, Proprietary Molecular Test For Hematologic Cancers

Impacts a $100M annual US laboratory market by reducing testing costs through a simple, screening assay NEW HAVEN, CT, (October 3rd, 2018) – Specialty cancer diagnostics [...]

Read More
Precipio Granted 180 Day NASDAQ Extension To Regain Compliance

Enables Company to execute on strategic and commercial initiatives with the goal of meeting the minimum $1.00 price target NEW HAVEN, CT, (September 27th, 2018) – [...]

Read More
Precipio Expands ICE-COLD PCR™ Lung Cancer Mutation Detection Offering

New reagent examines most relevant EGFR exons that impact therapeutic decisions for lung cancer patients NEW HAVEN, CT, (September 20th, 2018) – Specialty cancer diagnostics company Precipio, [...]

Read More
Precipio Announces Third Quarter 2018 Revenues Estimated At 2.4 Times Year-Over-Year Q3-2017

Fourth consecutive Quarter of Triple-Digit YoY Quarterly Growth; Triple YTD Revenues Over Same Period Last Year NEW HAVEN, CT, (October 16th, 2018) – Specialty cancer diagnostics [...]

Read More
Precipio Reminds Investors Of Conference Call With Management For Corporate Update And Second Quarter Results

Provides participation details for Thursday, August 23 call NEW HAVEN, CT, (August 22nd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), wishes to remind investors and [...]

Read More
Precipio Announces Second Quarter 2018 Financial Results And Provides Corporate Update

Conference call with management to be held Thursday August 23, 2018 at 09:00 Eastern Time NEW HAVEN, CT, (August 17th, 2018) – Specialty cancer diagnostics company Precipio, [...]

Read More
Precipio Appoints New Board Member To Replace Departing Director

Kathy LaPorte brings 30-year track record of VC success financing and operating innovative biopharma, diagnostics and healthcare companies NEW HAVEN, CT, (August 09th, 2018) – Specialty [...]

Read More
Precipio Announces 213% Year-Over-Year Revenue Growth In Preliminary Q2-2018 Results

Third consecutive quarter of triple-digit YoY Quarterly growth NEW HAVEN, CT, (July 18th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced preliminary second quarter [...]

Read More
Precipio And Nucleai Partner To Develop Artificial Intelligence-Powered Hemepath Solution

System will support Hematopathologists in accurately identifying abnormalities to ensure diagnostic accuracy NEW HAVEN, CT, (June 26th, 2018) – Precipio, Inc. (NASDAQ: PRPO), announced today an agreement with [...]

Read More
Precipio Updates Commercial Pipeline For Its ICE-COLD PCR™ Liquid Biopsy Technology

Trials underway at five laboratories and two diagnostic equipment companies NEW HAVEN, CT, (June 19th, 2018) – Precipio, Inc. (NASDAQ: PRPO), today detailed its pipeline of high-volume potential [...]

Read More
Precipio Inc. Announces Adjournment Of Annual Meeting Of Shareholders

NEW HAVEN, CT, (June 15th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that the Company’s 2018 Annual Meeting of Shareholders, originally scheduled for [...]

Read More
Precipio Reminds Shareholders To Vote Before The Annual General Meeting On June 15, 2018

NEW HAVEN, CT, (June 14th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today reminded its shareholders to vote on proposals 1-6 in accordance with the [...]

Read More
Precipio Reminds Shareholders To Vote Before The Annual General Meeting On June 15, 2018

NEW HAVEN, CT, (June 12th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today reminded its shareholders to vote on proposals 1-6 in accordance with the [...]

Read More
Precipio Strengthens Patent Portfolio With Expanded Reagent Claims For Its Liquid Biopsy Enabling DNA Mutation Enrichment Technology

NEW HAVEN, CT, (June 06th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the award of US patent No. 9,957,556 entitled FULL COLD-PCR ENRICHMENT [...]

Read More
Precipio Launches Liquid Biopsy DNA Enrichment Sales In Europe With First Order

$10 million annual Europe market anticipated with $1 million annual addressable sales potential from local Italy partner/i> NEW HAVEN, CT, (May 24th, 2018) – Specialty cancer [...]

Read More
Potential Sequential Revenue Run-Rate Growth Of 30% Over Q1, Based On Preliminary April Results

Revenue growth accelerating as new sales initiatives and expanded team gain traction NEW HAVEN, CT, (May 22nd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today [...]

Read More
Precipio Launches ICE COLD-PCR™ Liquid Biopsy Reagent For Pancreatic Cancer

Ultra-sensitive enrichment reagent enables development of low cost detection tests, allowing optimized patient treatment NEW HAVEN, CT, (May 17th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Read More
Precipio Announces Preliminary Q1 2018 Year-Over-Year Revenue Increase Of 286%

Growth resulting from commercial team reorganization, product and service cross-selling, and increased business stabilization NEW HAVEN, CT, (May 14th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Read More
Precipio Announces Participation Details For Upcoming Shareholder Conference Call

NEW HAVEN, CT, (April 26th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), provides details of its previously announced upcoming shareholder conference call scheduled for Monday [...]

Read More
Precipio Completes A $3M Convertible Debt Facility

Management focuses on growth opportunities NEW HAVEN, CT, (April 23rd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it entered into a convertible [...]

Read More
Precipio In Strategic Partnership Discussions For Proprietary Cytogenetics Media IV-Cell

NEW HAVEN, CT, (April 18th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today it is in active licensing discussions with several potential partners regarding [...]

Read More
Precipio Releases Its 2017 10-K, Files A Form S-1, And Hosts Fourth Quarter And Full Year Update Call

Management to provide strategic business update to shareholders NEW HAVEN, CT, (April 17th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that on April [...]

Read More
Precipio Launches ICE COLD-PCR™ Research Access Program For Cancer Centers

Complimentary Precipio ICE COLD PCR™ reagents now available to advance body of research and accelerate market expansion NEW HAVEN, CT, (April 11th, 2018) – Specialty cancer [...]

Read More
Important JAMA Article Underscores Superiority Of Precipio’s Liquid Biopsy Core Technology

Study cites major accuracy flaws in predominant liquid biopsy platforms offered by competitors NEW HAVEN, CT, (April 03rd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]

Read More
Precipio Files Patent For Non-Invasive Cell Capture Device For Gynecological Cancer Detection

In collaboration with Yale, feminine panty liner designed to remove obstacles to early detection NEW HAVEN, CT, (March 28th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]

Read More
Precipio Enters India Liquid Biopsy Market With Adoption By Leading Laboratory

CORE Diagnostics to transition to Precipio’s price competitive ICE COLD-PCR™ platform NEW HAVEN, CT, (March 26th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced [...]

Read More
Precipio Restructures Capitalization Table

Investors to convert preferred shares and exercise warrants NEW HAVEN, CT, (March 22nd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), in an 8-K issued today [...]

Read More
Precipio Integrates Cost Reducing And Fast Turnaround “High Resolution Melt” Into Liquid Biopsy Platform

Enhances competitive advantage as industry’s most cost effective solution NEW HAVEN, CT, (March 20th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today it has [...]

Read More
Precipio Settles Lawsuit With Crede Capital

Completes Restructuring of close to 95% Transgenomic Liabilities NEW HAVEN, CT, (March 13th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today it has settled [...]

Read More
Key Measure Of Precipio’s Pathology Sales Growth 4X Prior Quarter

Strong indications of academic-level pathology market adoption and sales uptake NEW HAVEN, CT, (February 22nd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that [...]

Read More
Precipio Launches Unique Lung Cancer Monitoring Test For Therapy Resistance

New test fulfills promise of liquid biopsies to cost effectively monitor patients NEW HAVEN, CT, (February 15th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced [...]

Read More
Precipio Announces Q4 2017 Revenue At 350% Of Previous Quarter

First post-merger quarter to turn the corner and demonstrate growth NEW HAVEN, CT, (February 09th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces preliminary, unaudited [...]

Read More
Precipio Enters Japanese Liquid Biopsy Market With First Hospital Sale

First ICE-COLD PCR™ order generated from distribution partnership with Sowa Trading Company NEW HAVEN, CT, (February 06th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces [...]

Read More
Precipio Commences Validation Study Of Proprietary IV-Cell Cytogenetics Media At University Of Pennsylvania

NEW HAVEN, CT, (January 22nd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced it is collaborating with the cytogenetics laboratory at the University of [...]

Read More
Precipio Appoints New Sales VP To Manage Diagnostics Sales Expansion

Sales growth acceleration plan to triple size of oncologist/hospital sales team in 2018 NEW HAVEN, CT, (January 16th, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]

Read More
Yale Study Demonstrates Four-Fold Superiority Of Academic Level Diagnostic Accuracy

Study further shows ~73% of cases which academic pathologists determined were previously misdiagnosed, have definite or possible material impact on patient treatment plans NEW HAVEN, [...]

Read More